Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More
Department
LocationCancer and Hematology Center
Liver Tumor Program
Bone Marrow Transplant / Stem Cell Transplant Program
Neuroblastoma Program
Solid Tumor Programs
Texas Medical Center
Specialty
Cancer
Phone: 832-822-4242
Fax: 832-825-1453
Email
axheczey@texaschildrens.org
Address
1102 Bates Ave., Ste. 1760.10
Houston, TX 77030
Research Laboratory
Andras A. Heczey, MD
Director, Liver Tumor Program
Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Baylor College of Medicine | Fellowship | Pediatric Hematology Oncology | 2012 |
| Children's Hospital of Los Angeles | Residency | Pediatrics | 2009 |
| Semmelweis Medical University, Hungary | Residency | Infectious Disease | 2006 |
| Semmelweis University | Medical School | Doctor of Medicine | 2002 |
About
Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology/Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).
News Articles
Organizations
| Organization Name | Role |
|---|---|
| American Society of Cell and Gene Therapy (ASCGT) | Member |
| American Society of Clinical Oncology (ASCO) | Member |
| American Society of Pediatric Hematology and Oncology (ASPHO) | Member |
| Children's Oncology Group (COG) | Member |
Research Statement
Dr. Andras Heczey's research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack and kill cancer cells by using genetically-engineered T cells and Natural Killer T cells.
As the Director of the Liver Tumor Center, Dr. Heczey developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically-engineered T lymphocytes. He is currently optimizing this strategy for a smooth transition into the clinic. He developed bispecific T cell engagers and chimeric antigen receptors which specifically target hepatoblastoma and hepatocellular carcinoma when expressed in T cells. His goal is to cure all patients with liver cancers by translating these methods from the laboratory setting to the patient care clinic.
In regards to neuroblastoma, Dr. Heczey studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells (NKT cells) that are genetically-modified to attack neuroblastoma. He aims to transition this approach from bench-to-bedside as a Phase 1/2a clinical trial.
Selected Publications
Awards & Honors
2000 Good Student and Good Athlete of the Republic of Hungary, Ministry of Education of Hungary
2009 Associates and Affiliates Award of the Children's Hospital of Los Angeles, for scientific knowledge, clinical judgment and excellence in human relations
2010 Tumor Board Award, Texas Children's Cancer and Hematology Center
2011-2012 Chief Fellow, Texas Children's Cancer and Hematology Center
2015 Fellows’ Excellence in Education Award, Texas Children's Cancer and Hematology Center
2017 Faculty Recognition Award, Texas Children’s Cancer and Hematology Center
2017 Biotherapeutics Award, Alex's Lemonade Stand Foundation
Board Certification
American Board of Pediatrics - General Pediatrics, American Board of Pediatrics - Pediatric Hematology and Oncology
Language
English
Latest Videos
Liver Tumor Program at Texas Children's Cancer Center
TARE procedure available for pediatric liver cancer patients at Texas Children's Hospital
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.